EA201390820A1 - Слитый белок против рака - Google Patents

Слитый белок против рака

Info

Publication number
EA201390820A1
EA201390820A1 EA201390820A EA201390820A EA201390820A1 EA 201390820 A1 EA201390820 A1 EA 201390820A1 EA 201390820 A EA201390820 A EA 201390820A EA 201390820 A EA201390820 A EA 201390820A EA 201390820 A1 EA201390820 A1 EA 201390820A1
Authority
EA
Eurasian Patent Office
Prior art keywords
domain
fusion protein
sequence
against cancer
protein against
Prior art date
Application number
EA201390820A
Other languages
English (en)
Other versions
EA024452B1 (ru
Inventor
Ежи Щепан Печиколан
Кшиштоф Казимеж Лемке
Себастьян Павлак
Бартломей Жерек
Original Assignee
Адамед Сп. З О.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL393146A external-priority patent/PL393146A1/pl
Application filed by Адамед Сп. З О.О. filed Critical Адамед Сп. З О.О.
Publication of EA201390820A1 publication Critical patent/EA201390820A1/ru
Publication of EA024452B1 publication Critical patent/EA024452B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

Слитый белок, содержащий домен (а), который представляет собой функциональный фрагмент белковой последовательности hTRAIL, который начинается с аминокислоты в положении не ниже hTRAIL95, или гомолог указанного функционального фрагмента, имеющий по меньшей мере 70% идентичность последовательности; и домен (b), который представляет собой последовательность иммуностимулирующего эффекторного пептида, где последовательность домена (b) связана с С-концом или N-концом домена (а). Слитый белок можно использовать для лечения раковых заболеваний.
EA201390820A 2010-12-03 2011-12-05 Слитый белок против рака EA024452B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL393146A PL393146A1 (pl) 2010-12-03 2010-12-03 Przeciwnowotworowe białko fuzyjne
PL39459711 2011-04-18
PCT/EP2011/071719 WO2012072815A1 (en) 2010-12-03 2011-12-05 Anticancer fusion protein

Publications (2)

Publication Number Publication Date
EA201390820A1 true EA201390820A1 (ru) 2013-12-30
EA024452B1 EA024452B1 (ru) 2016-09-30

Family

ID=45065918

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390820A EA024452B1 (ru) 2010-12-03 2011-12-05 Слитый белок против рака

Country Status (27)

Country Link
US (1) US9161991B2 (ru)
EP (1) EP2646464B1 (ru)
JP (1) JP5759557B2 (ru)
KR (1) KR101952460B1 (ru)
CN (1) CN103237808B (ru)
AU (1) AU2011334868B2 (ru)
BR (1) BR112013013548B8 (ru)
CA (1) CA2814595C (ru)
CY (1) CY1116646T1 (ru)
DK (1) DK2646464T3 (ru)
EA (1) EA024452B1 (ru)
ES (1) ES2545895T3 (ru)
HK (1) HK1186192A1 (ru)
HR (1) HRP20150664T1 (ru)
HU (1) HUE027068T2 (ru)
IL (1) IL226207A (ru)
ME (1) ME02224B (ru)
MX (1) MX337436B (ru)
NZ (1) NZ609216A (ru)
PL (1) PL2646464T3 (ru)
PT (1) PT2646464E (ru)
RS (1) RS54057B1 (ru)
SG (2) SG189370A1 (ru)
SI (1) SI2646464T1 (ru)
SM (1) SMT201500203B (ru)
WO (1) WO2012072815A1 (ru)
ZA (1) ZA201303449B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
AU2020258384A1 (en) 2019-04-15 2021-11-04 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
EP4133085A1 (en) 2020-04-10 2023-02-15 CytomX Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
IL305716A (en) 2021-03-16 2023-11-01 Cytomx Therapeutics Inc Activated garaged cytokine constructs and related compositions and methods
KR20230169700A (ko) 2022-06-09 2023-12-18 제주대학교 산학협력단 Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
IL122408A0 (en) 1995-06-29 1998-06-15 Immunex Corp Dna encoding a trail polypeptide and its preparation
AU2001269762C1 (en) * 2000-06-09 2005-12-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
AU2001288025A1 (en) * 2000-09-05 2002-03-22 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2003280921B2 (en) 2003-11-03 2007-09-13 Beijing Sunbio Biotech Co., Ltd. A recombinant protein with cancer suppression action, its encoding gene and use
WO2007022157A2 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
EP2484691B1 (en) * 2007-07-10 2016-01-13 Apogenix GmbH TNF superfamily collectin fusion proteins
JP6035009B2 (ja) * 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
US7943733B2 (en) 2007-12-20 2011-05-17 University Of Southern California Spacers to increase the expression of recombinant fusion proteins
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme

Also Published As

Publication number Publication date
MX337436B (es) 2016-03-03
KR20130122764A (ko) 2013-11-08
EP2646464A1 (en) 2013-10-09
SI2646464T1 (sl) 2015-07-31
BR112013013548B8 (pt) 2022-11-08
HUE027068T2 (en) 2016-08-29
AU2011334868B2 (en) 2015-01-22
SG189370A1 (en) 2013-05-31
ES2545895T3 (es) 2015-09-16
RS54057B1 (en) 2015-10-30
BR112013013548A2 (pt) 2016-10-11
CN103237808A (zh) 2013-08-07
US20130251676A1 (en) 2013-09-26
CY1116646T1 (el) 2017-03-15
BR112013013548B1 (pt) 2022-03-29
EP2646464B1 (en) 2015-06-03
IL226207A (en) 2016-07-31
MX2013006213A (es) 2013-07-29
AU2011334868A1 (en) 2013-05-02
EA024452B1 (ru) 2016-09-30
CA2814595C (en) 2020-06-16
JP2014502158A (ja) 2014-01-30
HRP20150664T1 (hr) 2015-07-31
SG10201509676UA (en) 2015-12-30
ZA201303449B (en) 2014-01-29
US9161991B2 (en) 2015-10-20
DK2646464T3 (en) 2015-08-24
SMT201500203B (it) 2015-10-30
IL226207A0 (en) 2013-07-31
HK1186192A1 (en) 2014-03-07
JP5759557B2 (ja) 2015-08-05
PL2646464T3 (pl) 2015-10-30
NZ609216A (en) 2014-05-30
KR101952460B1 (ko) 2019-02-27
CA2814595A1 (en) 2012-06-07
WO2012072815A1 (en) 2012-06-07
PT2646464E (pt) 2015-10-05
ME02224B (me) 2016-02-20
CN103237808B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
EA201390820A1 (ru) Слитый белок против рака
EA201491049A1 (ru) Противораковый слитый белок
EA201391005A1 (ru) Слитый белок против злокачественной опухоли
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
EA201491277A1 (ru) Противораковый слитый белок
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
EA201270517A1 (ru) Микобактериальные вакцины
RU2021134101A (ru) Модифицированная j-цепь
BR112016011025A2 (pt) polipeptídeos anticorpo e seus usos
UA107330C2 (ru) Туберкулезный белок rv3616c и его применение
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
EA201391546A1 (ru) Противораковый слитый белок
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
MX2016000393A (es) Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
EA201291345A1 (ru) Цитруллинированные гистоновые пептиды и их применение
WO2015043566A8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
EA201290384A1 (ru) Вирусные цитруллинированные пептиды и их применение
MX2016002556A (es) Métodos y composiciones para el tratamiento de patologías del tejido de cartílago y disco.
UA108911C2 (xx) Протираковий злитий протеїн
BR112013011285A2 (pt) vacina
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
WO2015143339A3 (en) Enhanced influenza hemagglutinin binders